Compare Summit Therapeutics Inc (SMMT) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs VNET Group Inc — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: Summit Therapeutics Inc is far larger — about 9.3× VNET Group Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and VNET Group Inc for 16 Days on average.
| SMMT | VNET | |
|---|---|---|
Market Cap | $13.71B | $1.47B |
Volume | 6,173,057 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $26.38 | $14.03 |
52-Week Low | $12.43 | $5.13 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $13.04B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
VNET trades at $5.42, up 0.56% today but near a 52-week low. Technicals are bearish with moving averages signaling sell, while fundamentals show revenue growth to $9.95B in 2025 but net losses of $256.77M. Recent news includes a strategic investment closing and a new low, reflecting mixed sentiment amid high institutional interest and negative cash flow trends.
Outlook: Strategic partnerships and AI demand offer growth, but high debt, negative margins, and bearish technicals pose significant risks. Analyst consensus is moderately bullish (62.5% buy), yet profitability challenges and leverage require caution for investors seeking turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
